Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Intraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia|
|Citation:||Eye, 2013; 27(4):561-563|
|Publisher:||Nature Publishing Group|
|NH Andrew, D Kearney and D Selva|
|Abstract:||PURPOSE The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH). PATIENTS AND METHOD Retrospective, single-centre, interventional case series. RESULTS Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection. CONCLUSION Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.|
|Keywords:||reactive lymphoid hyperplasia; lymphoproliferative disorders; corticosteroid; drug therapy; orbital disease|
|Rights:||© 2013 Macmillan Publishers Limited All rights reserved|
|Appears in Collections:||Opthalmology & Visual Sciences publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.